Emanuele Carloni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emanuele Carloni has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Amedeo Caflisch
University of Zürich
1 shared publication - Cristina Nevado
Department of Chemistry, University of Zürich, Zürich, Switzerland
1 shared publication - Eleen Laul
University of Zürich
1 shared publication - Irene Latino
Università della Svizzera Italiana
1 shared publication - Katherine Gosselé
University of Zürich
1 shared publication - Mariia S. Kirillova
University of Zürich
1 shared publication
Latest Publications
- Open Access
- 26 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling
Tumor Necrosis Factor α (TNF-α) is an inflammatory cytokine that is a key mediator in autoimmune disorders such as Crohn’s disease and rheumatoid arthritis (RA). Targeting epigenetic regulators of cytokine transcription and signaling is a promising therapeutic approach. However, the specific mechanisms by which they contribute to the immune response are not well established yet. Here, we present a new class of selective CBP/EP300-bromodomain (BRD) inhibitors comprising a 3-methylcinnoline as acetyl-lysine mimic discovered by high-throughput docking of a fragment library. These compounds inhibit NFκB signaling in THP-1 cells, reducing TNF-α-induced cytokine expression in vitro. Furthermore, when tested in vivo, BRD inhibitors reduced the pro-inflammatory response by decreasing the secretion of IL-1β, MCP-1, IL-1α, and IL-6 from TNF-α-stimulated animals and inhibiting the migration of innate immune cells towards the draining lymph node. The results of this study confirmed CBP/EP300-BRD as valid therapeutic targets for autoimmune diseases and our inhibitors represent a promising new class of non-cytotoxic therapeutic agents for treating RA.
- 26 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling
Tumor Necrosis Factor α (TNF-α) is an inflammatory cytokine that is a key mediator in autoimmune disorders such as Crohn’s disease and rheumatoid arthritis (RA). Targeting epigenetic regulators of cytokine transcription and signaling is a promising therapeutic approach. However, the specific mechanisms by which they contribute to the immune response are not well established yet. Here, we present a new class of selective CBP/EP300-bromodomain (BRD) inhibitors comprising a 3-methylcinnoline as acetyl-lysine mimic discovered by high-throughput docking of a fragment library. These compounds inhibit NFκB signaling in THP-1 cells, reducing TNF-α-induced cytokine expression in vitro. Furthermore, when tested in vivo, BRD inhibitors reduced the pro-inflammatory response by decreasing the secretion of IL-1β, MCP-1, IL-1α, and IL-6 from TNF-α-stimulated animals and inhibiting the migration of innate immune cells towards the draining lymph node. The results of this study confirmed CBP/EP300-BRD as valid therapeutic targets for autoimmune diseases and our inhibitors represent a promising new class of non-cytotoxic therapeutic agents for treating RA.